Novartis has again been recognized for its commitment to doing well by doing good in key global rankings. Fortune’s “Change the World” list, published online on Thursday, September 7, placed Novartis in fourth place out of 50 companies listed.
Novartis has joined more than 20 leading biopharmaceutical companies to launch “Access Accelerated”, a global initiative to further advance access to prevention and care for noncommunicable diseases in low and lower-middle income countries. Chronic conditions such as heart disease and cancer are a growing threat in the world’s poorest countries.
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...
The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...
